Stockreport

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer [Yahoo! Finance]

AstraZeneca PLC - American Depositary Shares  (AZN) 
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm Check Earnings Report
US:NYSE Investor Relations: astrazeneca.com/investor-relations.html
PDF WILMINGTON, Del., March 31, 2025 BUSINESS WIRE )--AstraZeneca's IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed [Read more]